SummitTX Capital’s Janux Therapeutics JANX Stock Holding History

SummitTX Capital’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-15,909	Closed	-$367K	–	869
2025 Q2	$367K	Buy	+15,909	New	+$419K	0.02%	570

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SummitTX Capital's JANX Position: Q3 2025 in Review

SummitTX Capital sold out of Janux Therapeutics (JANX) in Q3 2025, closing a stake of 15,909 shares — an estimated $367K sold.

SummitTX Capital first reported a position in JANX in Q2 2025 and held it in 1 quarter. The position peaked at $367K in Q2 2025. 174 funds tracked by Wall St. Rank hold JANX as of Q3 2025.

SummitTX Capital reported no remaining Janux Therapeutics position as of Q3 2025 after selling out during the quarter.
SummitTX Capital sold 15,909 Janux Therapeutics shares in Q3 2025, an estimated $367K.
SummitTX Capital first reported a position in Janux Therapeutics in Q2 2025 and held it in 1 quarter.
SummitTX Capital's Janux Therapeutics position peaked at $367K in Q2 2025.
174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q3 2025.

Based on SummitTX Capital's 13F filing for Q3 2025, filed 14 Nov 2025.